Becton, Dickinson and Company (NYSE:BDX – Get Rating) – William Blair issued their Q1 2023 earnings estimates for shares of Becton, Dickinson and in a note issued to investors on Thursday, May 5th. William Blair analyst B. Weinstein forecasts that the medical instruments supplier will earn $3.25 per share for the quarter. William Blair also issued estimates for Becton, Dickinson and’s Q2 2023 earnings at $3.44 EPS, Q4 2023 earnings at $3.84 EPS and FY2023 earnings at $14.15 EPS.
Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.99 by $0.19. The company had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $3.19 EPS.
NYSE:BDX opened at $257.97 on Monday. The stock has a market capitalization of $73.46 billion, a PE ratio of 40.69, a price-to-earnings-growth ratio of 3.21 and a beta of 0.64. The business’s 50-day simple moving average is $263.40 and its 200-day simple moving average is $257.30. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.53 and a quick ratio of 0.78. Becton, Dickinson and has a fifty-two week low of $235.13 and a fifty-two week high of $280.62.
A number of large investors have recently made changes to their positions in the stock. Accel Wealth Management grew its stake in shares of Becton, Dickinson and by 100.0% in the 4th quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 50 shares during the last quarter. Sierra Capital LLC grew its stake in shares of Becton, Dickinson and by 88.7% in the 4th quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. Level Financial Advisors Inc. bought a new position in Becton, Dickinson and in the 4th quarter valued at approximately $26,000. Icapital Wealth LLC bought a new position in Becton, Dickinson and in the 1st quarter valued at approximately $31,000. Finally, Disciplined Investments LLC bought a new position in Becton, Dickinson and in the 1st quarter valued at approximately $32,000. Institutional investors own 86.58% of the company’s stock.
In other news, Director Claire Fraser sold 841 shares of the business’s stock in a transaction dated Tuesday, February 8th. The stock was sold at an average price of $271.70, for a total value of $228,499.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Betty D. Larson sold 14,374 shares of the business’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The disclosure for this sale can be found here. 0.50% of the stock is owned by insiders.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be given a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.35%. Becton, Dickinson and’s payout ratio is 54.89%.
About Becton, Dickinson and (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.